Search

everythinglearnresearchcommunity

for

Search:↓

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Fluridil is considered safe with moderate effectiveness for hair loss, but its cost of €50 per month is seen as high compared to other treatments. The user is considering Pyri as a more cost-effective option and is seeking success stories about Fluridil's ability to stop hair loss without side effects.

Noxidil from Zeemoreuncle appears legitimate based on a bleach test with oral minoxidil tablets. The test results showed an instant color change, suggesting the product's authenticity.

Morr F Aqua, an alcohol-free Minoxidil, is discussed for its absorption effectiveness. Users also mention using finasteride and RU58841 for hair loss treatment.

Minoxidil turned yellow/orange when mixed with bleach, suggesting its presence. However, this doesn't confirm the concentration of minoxidil.

A user is developing a tool to track hair density, aiming to help those using treatments like minoxidil. They seek feedback on the tool's usefulness and are considering a low-cost model to cover expenses.

Best 2% Minox brand for mixing with pyrilutamide powder and retinoic acid sought. Advice on specific treatments discussed.

The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.

A user experienced accelerated hairline recession after adding dutasteride to their regimen of topical finasteride and minoxidil, despite reduced hair shedding. They were informed that ELISA testing for DHT levels can be highly inaccurate.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

The user is using minoxidil and recently started fluridil for mild hair loss and is questioning if this treatment is sufficient without finasteride. They have finasteride available but prefer not to use it.

The conversation is about whether testing for free DHT is necessary before starting Finasteride for hair loss, despite having other hormone tests available. One person suggests that genetic response to DHT is more important than DHT levels and advises starting Finasteride without the free DHT test.

User considers adding Alfatradiol to their topical finasteride treatment for hair loss. Others discuss Alfatradiol as a weak estrogen and 5α-reductase inhibitor used for pattern hair loss in men and women.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

A user created oral minoxidil sugar cubes due to lack of prescription access, leading to a humorous discussion about unconventional and potentially unsafe methods of using minoxidil. The conversation highlights the lengths people go to for hair growth.

Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.

The conversation is about the effectiveness of alfatradiol for hair loss and whether it can be used with or as a replacement for common treatments like minoxidil, finasteride, and RU58841. The user is seeking feedback on others' experiences with alfatradiol.

The user wants to try using 0.025% topical finasteride every day by diluting their 0.1% topical finasteride with alfatradiol, and is asking if it's possible to mix them or if there are other options. They heard that alfatradiol might not be suitable for this purpose.

The conversation discusses using Morr F Aqua, an alcohol-free version of Minoxidil, for hair loss, particularly for someone with dandruff issues. The user is considering if this product is suitable for their condition.

The user has been using 1mg finasteride and 2.5mg oral minoxidil daily for 18 months without success in treating hair loss. They are frustrated with their diffuse androgenetic alopecia and unsure of what to do next.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

Pyrilutamide's systemic degradation is unclear, unlike fluridil, which becomes inactive in the body. The discussion focuses on whether pyrilutamide shares this property.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.

The user experienced significant hair regrowth over five months using Locklabs oral tablets, with no side effects and only a minor shed. They dye their hair black to cover natural blonde, which may affect perceived hair density.

Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.

Minoxidil sulfate is considered for those unresponsive to regular minoxidil, with some trying a 10% formulation from Folligenz. Concerns exist about the product's stability and transparency, but some users report positive initial results.

User shared a 2-year progress update on hair regrowth using 1mg finasteride and 2.5mg oral minoxidil daily. They switched from topical to oral minoxidil for ease of use and showed significant improvement.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.